Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organoids & Microphysiological Systems 2022

Organoids & Microphysiological Systems 2022 Agenda

Co-Located Conference Agendas

Extracellular Vesicles 2022: Technologies Driving Biological Investigations | Lab-on-a-Chip and Microfluidics World Congress 2022 | Organoids & Microphysiological Systems 2022 | Point-of-Care & Rapid Diagnostics 2022 | 

Print Agenda

Monday, 12 December 2022

Please View Agenda for Plenary Session in the Lab-on-a-Chip Track Website

Tuesday, 13 December 2022

Please View Agenda for Microfluidics-Lab-on-a-Chip Programming in the Lab-on-a-Chip Track Website

Wednesday, 14 December 2022


Morning Coffee, Tea and Pastries in the Exhibit Hall

Lab-on-a-Chip, Microfluidics, Organs-on-Chips -- Connecting the Dots


Microfluidic Encapsulation of Therapeutic Agents in Microdroplets and Nanoparticles
Dong Pyo Kim, Yonsan Chaired Professor, Pohang University of Science And Technology (POSTECH), Korea South

Microdroplets (µ-droplet) and nanoparticles (NPs) have been attracted significant interest in the past decades to address different drug delivery challenges, including poor bioavailability, poor drug solubility, and lack of targeted delivery. Traditionally, µ-droplet and NPs are often produced using bulk methods. In comparison, microfluidics offers a new strategy for making µ-droplet and NPs with controlled shape and homogeneous size due to rapid mass transfer and precise control over reaction conditions. Herein, we present a continuous-flow method for effectively encapsulating various therapeutic agents (enzymes, chelators, magnetic nanoparticles, bio-imaging agents, etc.) into uniform size of polymeric µ-droplet and inorganic NPs by microfluidics. Furthermore, we controlled the mixing time between the reactants of carrier and the therapeutic agent by forming various flow patterns (chaotic, multiple-laminar flow) and developed a drug delivery system with an improved therapeutic effect through flow control. This work will contribute effective encapsulation of therapeutic agents in µ-droplet and NPs, which would be extended to biomedical applications.


Fluid Handling System for Lab-on-a-Chips
Felipe Echeverri, CEO, Biorep Technologies, Inc., United States of America

Proven technology for dynamic perifusion studies can be adapted for Lab-on-a-Chip applications – A System Overview.

Session Title: The MPS Field Radiating Out from the Microfluidics Area


George TruskeyKeynote Presentation

Human Microphysiological Systems for Disease Modeling
George Truskey, R. Eugene and Susie E. Goodson Professor of Biomedical Engineering, Duke University, United States of America

Microphysiological systems (MPS) are small scale three-dimensional models of key structural or functional units of human organs or tissues.  Such systems can be used to model diseases and test therapeutics.  The strengths and limitations of various models will be discussed with a focus on vascular models, including system design and the use of primary and stem cell derived cells.  Applications of these systems to model genetic and acquired diseases and evaluate therapeutics will be described.


Noo Li JeonKeynote Presentation

All-in-one Microfluidic Design to Integrate Vascularized Tumor Spheroid into High-Throughput Platform
Noo Li Jeon, Professor, Seoul National University, Korea South

The development of a scalable and highly reproducible in vitro tumor microenvironment (TME) platform still sheds light on new insights into cancer metastasis mechanisms and anticancer therapeutic strategies. Here, we present an all-in-one injection molded plastic array three-dimensional culture platform (All-in-One-IMPACT) that integrates vascularized tumor spheroids for highly reproducible, high-throughput experimentation. This device allows the formation of self-assembled cell spheroids on a chip by applying the hanging drop method to the cell culture channel. Then, when the hydrogel containing endothelial cells and fibroblasts is injected, the spheroid inside the droplet can be patterned together in three dimensions along the culture channel. In just two steps above, we can build a vascularized TME within a defined area. This process does not require specialized user skill and minimizes error-inducing steps, enabling both reproducibility and high throughput of the experiment. We have successfully demonstrated the process, from spheroid formation to tumor vascularization, using patient-derived cancer cells (PDCs) as well as various cancer cell lines. Furthermore, we performed combination therapies with Taxol (paclitaxel) and Avastin (bevacizumab), which are used in standard care for metastatic cancer. The All-in-One IMPACT is a powerful tool for establishing various anticancer treatment strategies through the development of a complex TME for use in high-throughput experiments.


Engineering of Organotypic Tissue On-Chip Systems for Disease Modeling and Drug Testing
Mehdi Nikkhah, Associate Professor of Bioengineering, Arizona State University, United States of America

Engineering of ex vivo Tissue-On-Chip Technologies and Microphysiological Systems has gained significant attention in recent years for a wide range of applications in disease modeling, drug screening, and personalized medicine. These technologies have immensely benefited the fields of experimental biology and medicine in the ability to address the limitations of animal models by providing precise control over cell-cell, cell-matrix, and cell-microenvironmental factors interactions. In the past few years, we have been extensively involved in the development of next-generation tissue on-chip technologies through the integration of microfluidic systems, 3D biomaterials, and patient-derived cells. We have successfully engineered and validated numerous disease-on-chip models, including tumor-on-chip and heart-on-chip technologies, to study cancer progression and cardiovascular abnormalities. Using these model systems, we have been able to mechanistically investigate how microenvironmental and genetic risk factors lead to disease progression. Additionally, we have shown the capabilities of these model systems for enhanced drug testing. This seminar will provide an overview of our major findings from these projects.


The Benefits of Being Thin: How Ultrathin Silicon Membranes are Enabling New Technologies for Discovery in Biomedical Research
James McGrath, Professor of Biomedical Engineering, University of Rochester, United States of America

A decade-and-a-half after we first used silicon microfabrication to create free-standing ultrathin nanoporous membranes, the materials are being utilized by a growing number of laboratories as uniquely capable tools for biomedical research. Today we manufacture a variety of silicon-based nanoporous and microporous membranes with the common characteristics that they are ultrathin (15 nm - 300 nm) with well-defined pore sizes. The extremes thinness of 'nanomembranes' makes them orders-of-magnitude more permeable to both diffusing molecules and pressurized flow than conventional membranes. The ultrathin nature of the membranes also gives them a glass-like imaging quality in optical microscopy. These properties provide abundant opportunities for novel membrane-based devices and assays. This talk will provide an overview of two leading applications of our nanomembranes. First is their use to create in vitro models of human tissue (i.e. 'tissue chips' or 'microphysiological systems' where they provide optically transparent and highly permeable scaffolds to compartmentalize tissues including the brain neurovascular unit, the blood-retinal-barrier, bone, and tendon. The second application I will cover is the use of as tool for diagnostic applications. Here we have leveraged our understanding of filtration to develop a digital assay of extracellular vesicle biomarkers and pressure-based sensor that detects virus in a point-of-care microdevice.


Matthias von HerrathKeynote Presentation

Liraglutide Protects Human Beta-Cell Function From Cytokine- And Immune Cell-Induced Stress In Human In Vitro Models of T1D
Matthias von Herrath, Vice President and Senior Medical Officer, Novo Nordisk, Professor, La Jolla Institute, United States of America

GLP-1 receptor agonists (GLP-1 RA) are hypothesized to preserve beta-cell  function and enhance insulin secretion in type 1 diabetes (T1D). We evaluated the effects of the GLP-1 RA, liraglutide,  on reaggregated, uniform primary human islets under T1D-relevant stress. We established three high-throughput-compatible islet-immune injury models: a cytokine-induced stress assay, an activated peripheral blood mononuclear cell-islet co-culture, and an islet-HLA-A2-restricted preproinsulin-specific cytotoxic T lymphocyte co-culture. In all models, the decline in beta-cell health manifested as increased basal and decreased glucose-stimulated insulin release and decreased total insulin content. Liraglutide prevented loss of stimulated insulin secretion under cytokine- and immune-mediated stress, most notably by preserving the first-phase insulin response and decreasing immune cell infiltration and cytokine secretion. Our results corroborate the therapeutic potential of liraglutide for the preservation of beta-cell function at the time of T1D onset, provide further evidence of a GLP1-related anti-inflammatory effect, and support the utility of biomimetic islet-immune assays.


Shannon MumenthalerKeynote Presentation

Cancer-on-a-Chip Model of Colorectal Cancer Progression
Shannon Mumenthaler, Assistant Professor of Medicine & Biomedical Engineering, University of Southern California, Ellison Institute, United States of America

The highly complex and evolving nature of cancer makes it challenging to study. Here we describe a microfluidic organ-on-chip platform, incorporating tissue-tissue interfaces and physical forces, to support novel interrogations of colorectal cancer progression. We will cover advancements made through combining organoids and an organ-on-chip model with high content imaging and mass spectrometry-based metabolomics, which provide measurements that capture spatial and temporal cancer cell dynamics. This work reveals important interactions between colorectal cancer cells and their microenvironment, which can be used to prevent or delay cancer progression.


Janus Base Nano-matrix Enabled Cartilage-on-a-Chip for Drug Screening Applications
Yupeng Chen, Associate Professor, University of Connecticut, United States of America

To achieve biomimetic microenvironment for engineered tissues, it is important to have biomaterial scaffolds to support cell anchorage and functions. However, conventional solid scaffolds are not injectable so they have limitations for applications in “difficult-to-reach” locations, such as microchannels of tissues-on-chips or deep-tissue damage; hydrogels are semisolid materials so they don’t have solid surface for cell anchorage which could be a limitation in space. To overcome this challenge, we have developed a family of self-assembled scaffolds, named Janus base nano-matrices (JBNms). JBNms are formed by the self-assembly between Janus base nanotubes (JBNts, non-covalent nanotubes mimicking DNA base pairs) and extracellular matrix proteins (such as matrilin, a cartilage specific protein). We have also found that the JBNm presented synergistic functions from JBNts and matrilin, which can create a microenvironment selectively promoting chondrogenesis and stem cell differentiation. Moreover, the JBNm-enabled cartilage-on-a-chip demonstrated significantly improved reusability and longevity. These JBNm cartilage-on-chips can be used for disease modeling and drug screening for a variety of situations.


Danilo TagleKeynote Presentation

The NIH Microphyiological Systems Program: In Vitro 3D Models for Safety and Efficacy Studies
Danilo Tagle, Director, Office of Special Initiatives, National Center for Advancing Translational Sciences at the NIH (NCATS), United States of America

Approximately 30% of drugs have failed in human clinical trials due to adverse reactions despite promising pre-clinical studies, and another 60% fail due to lack of efficacy. A number of these failures can be attributed to poor predictability of human response from animal and 2D in vitro models currently being used in drug development. To address this challenges in drug development, the NIH Tissue Chips or Microphysiological Systems program is developing alternative innovative approaches for more predictive readouts of toxicity or efficacy of candidate drugs. Tissue chips are bioengineered 3D microfluidic platforms utilizing chip technology and human-derived cells and tissues that are intended to mimic tissue cytoarchitecture and functional units of human organs and systems. In addition to drug development, these microfabricated devices are useful for modeling human diseases, and for studies in precision medicine and environment exposures. Presentation will elaborate in the development and utility of microphysiologicals sytems and in the partnerships with various stakeholders for its implementation.


Networking Luncheon in the Exhibit Hall -- Network with the Exhibitors, View Posters and Engage with Colleagues

Add to Calendar ▼2022-12-12 00:00:002022-12-14 00:00:00Europe/LondonOrganoids and Microphysiological Systems 2022Organoids and Microphysiological Systems 2022 in Long Beach, CaliforniaLong Beach,